Meeting
2016 Gastrointestinal Cancers Symposium
A single institute retrospective trial of concurrent chemotherapy with SIR-Sphere versus SIR-Sphere alone in patients with chemotherapy-resistant colorectal cancer liver metastases.
Authors
May Thet Cho
City of Hope, Duarte, CA
May Thet Cho , Jonathan Kessler , John Park , Gagandeep Singh , Yi-Jen Chen , Philip HG Ituarte , Marwan Fakih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 770)
DOI
10.1200/jco.2016.34.4_suppl.770
Abstract #
770
Poster Bd #
O1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
First Author: Romain Cohen
Poster
2021 ASCO Annual Meeting
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).
First Author: Dominik Paul Modest
Poster
2018 ASCO Annual Meeting
Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).
First Author: Nicholas Adam Bosma
Poster
2023 ASCO Annual Meeting
Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma.
First Author: Paul Kent